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Atopic dermatitis and inflammatory skin diseaseNemolizumab in patients with moderate-to-
severe atopic dermatitis: Randomized, phase II,
long-term extension studyKenji Kabashima, MD, PhD,a Masutaka Furue, MD, PhD,b Jon M. Hanifin, MD,c Grazyna Pulka, MD,d
Andreas Wollenberg, MD,e Ryszard Galus, MD, PhD,f Takafumi Etoh, MD,g Ryosuke Mihara, MS,h
Miwa Nakano, MS,h and Thomas Ruzicka, MDe Kyoto, Fukuoka, and Tokyo, Japan; Portland, Ore; Cracow and Warsaw,
Poland; and Munich, GermanyBackground: Nemolizumab, an anti–IL-31 receptor A mAb,
improved pruritus, dermatitis, and sleep in adults with moderate-
to-severe atopic dermatitis that was inadequately controlled by
topical treatments in a phase II, 12-week, randomized, double-
blind, placebo-controlled study (part A; NCT01986933).
Objective: We sought to assess the long-term efficacy and safety
of nemolizumab injected subcutaneously every 4 weeks (Q4W)
or every 8 weeks (Q8W) in a 52-week, double-blind extension
(part B).
Methods: During part B, patients continued the previous
nemolizumab dose (0.1, 0.5, or 2.0 mg/kg Q4W or 2.0 mg/kg
Q8W). Part B end points included percentage improvement
from baseline in pruritus visual analog scale and dermatitis
scores (including the Eczema Area and Severity Index).
Results: Overall, 216 of 264 patients completed part A, and 191
entered part B; 131 completed part B. In 153 patients
randomized to nemolizumab in part A, improvement from
baseline in pruritus visual analog scale score was maintained/
increased from weeks 12 to 64, with greatest improvement in the
0.5-mg/kg Q4W group (percentage change from baseline at
week 64: 273.0, 289.6, 274.7, and 279.1 in the 0.1-, 0.5-, and
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maintained/increased to week 64 (percentage change in Eczema
Area and Severity Index score: 268.5, 275.8, 278.9, and 269.3
in the 0.1-, 0.5-, and 2.0-mg/kg Q4W and 2.0-mg/kg Q8W
groups, respectively). Over 64 weeks, 83% to 89% had 1 or
more adverse events, with no new safety concerns identified.
Conclusion: Nemolizumab for up to 64 weeks was efficacious
and overall well tolerated in patients with moderate-to-severe
atopic dermatitis inadequately controlled by topical therapy.
(J Allergy Clin Immunol 2018;142:1121-30.)
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Atopic dermatitis (AD) is a chronic, relapsing inflammatory
skin disease that leads to intensely pruritic disseminated skin
lesions that result frequently in severe scratching.1-4 Pruritus, the
dominant symptom of AD, can drive the itch-scratch cycle, which
further exacerbates the disease and leads to sleeplessness and
fatigue, which significantly affect quality of life (QoL).5,6 Topical
glucocorticoids, calcineurin inhibitors, or both are typically used
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1122 KABASHIMA ET ALAbbreviations usedAD: Atopic dermatitisAE: Adverse eventBSA: Body surface areaDLQI: Dermatology Life Quality IndexEASI: Eczema Area and Severity IndexIRR: Injection-related reactionQoL: Quality of lifeQ4W: Every 4 weeksQ8W: Every 8 weeksSAE: Serious adverse eventSCORAD: SCORing Atopic DermatitissIGA: Static Investigator’s Global AssessmentVAS: Visual analog scaleVRS: Verbal rating scalesymptom control in all patients, whereas systemic treatments
have been associated with long-term safety concerns.7-9 Despite
the US Food and Drug Administration’s recent approval of an
anti–IL-4 receptor a mAb, dupilumab, for moderate-to-severe
AD that is inadequately controlled by topical therapy, treatment
options are limited, and there remains an unmet need for novel
therapies with minimal long-term side effects.
Nemolizumab (CIM331) is an anti–IL-31 receptor
A humanized mAb that blocks signaling mediated by IL-31, a
proinflammatory cytokine associated with AD and pruritus.10-13
IL-31 is also associated with disruption of the physical skin
barrier, leading to greater penetration of allergens and
pathogens.14
Building on the promising results of a phase I trial,15
subcutaneous nemolizumab was assessed in a phase II,
12-week, randomized, double-blind, placebo-controlled,
dose-finding study in patients with moderate-to-severe AD
that was inadequately controlled by topical treatments
(NCT01986933).16 In the primary end point analysis, nemolizu-
mab administered every 4 weeks (Q4W) significantly improved
pruritus from baseline at week 12, as assessed by using the
pruritus visual analog scale (VAS). Percentage reductions in
pruritus VAS scores of 244% in the 0.1-mg/kg group, 260% in
the 0.5-mg/kg group, and 263% in the 2.0-mg/kg group were
reported versus 221% in the placebo group (P < .01 for all
comparisons). Improvements in AD disease severity and body
surface involvement, as well as sleep disturbance, were also
observed at week 12 versus placebo.16 Definitive conclusions
about adverse events (AEs) could not be drawn because of the
small patient sample and short follow-up period.
Here we describe a 52-week extension of that phase II trial to
assess the long-term efficacy and safety of continuous
subcutaneous nemolizumab when injected Q4Wor every 8 weeks
(Q8W).METHODS
Study design
This phase II trial (NCT01986933) was performed in 2 parts (Fig 1). Part A,
which was previously described,16 was a 12-week evaluation of 4 dose
regimens of nemolizumab, 0.1, 0.5, or 2.0mg/kg administered subcutaneously
Q4W and 2.0 mg/kg administered subcutaneously Q8W, or placebo
administered subcutaneously Q4W. On completion of part A, patients entered
the double-blind extension phase and continued to receive nemolizumab at the
previously assigned dose for a further 52weeks (weeks 12-64, part B). Patientsrandomized previously to placebo in part A were rerandomized to
nemolizumab (0.1, 0.5, or 2.0 mg/kg subcutaneous Q4W) in part B at a
1:1:1 ratio by using a centralized interactive voice or online response system
(placebo-treated patients were not rerandomized to nemolizumab 2.0 mg/kg
Q8W). All patients were required to enter part B within 7 days of the final visit
in part A. To maintain blinding in part B, the studymonitoring team, study site
personnel, and other site/company personnel remained blind to treatment
allocation until the final database after study completion was locked.
The study was performed in accordance with the guidelines for Good
Clinical Practice and the Declaration of Helsinki. Local ethics committee or
institutional review board approval was obtained for each study center.
Written informed consent was provided by all patients. The study was
performed at 57 sites in the United Kingdom,Germany, Poland, Japan, and the
United States between December 2013 and June 2016, and the database was
unblinded on September 9, 2016, for analysis of part B.Study population
Key inclusion criteria have been described previously (Fig 1).16 Patients
were required to have completed the part A treatment period and provided
written informed consent for participation in the extension phase to enter
part B. Patients who experienced a serious adverse event (SAE) considered
related to nemolizumab during part A of the study were not eligible for part B.Study procedures
In part B of the study, patients received treatment with 1 of 3 doses of
nemolizumab (0.1, 0.5, or 2.0 mg/kg) administered subcutaneously Q4W or
nemolizumab 2.0 mg/kg administered subcutaneously Q8W for 52 weeks. To
maintain blinding, patients receiving nemolizumab Q8W were administered
placebo at week 12 (last visit for part A), nemolizumab at week 16, and then
alternating doses of placebo and nemolizumab. Patients were permitted to
use emollients, localized treatments (eg, eye drops), mild topical
glucocorticosteroids (including prednisolone), topical calcineurin inhibitors,
and antihistamines (excluding nonselective H1 antihistamines). Patients with
little or no improvement in pruritus VAS scores (range, 0 mm [no itch] to
100 mm [worst imaginable itch]) and static Investigator’s Global Assessment
(sIGA) scores (range, 0 [clear] to 5 [very severe disease]) in the opinion of the
investigator were allowed to use a ‘‘potent’’ topical glucocorticosteroid,17 such
as mometasone furoate 0.1%, as a rescue therapy in part A (at or after week 4)
and a ‘‘potent’’ or ‘‘very potent’’ topical glucocorticosteroid, such as clobetasol
propionate 0.05%, in part B.Study assessments
Baseline assessments for patients rerandomized from placebo to
nemolizumab in part B were performed at the final visit of part A or at a
separate visit. Patients attended study visits Q4W from week 12 to week 64
and a safety follow-up visit 12 weeks (65 days) after the last dose of study
drug. For consistency, patients were evaluated by the same assessor (when
possible) at all visits. Assessor training was performed to minimize intersite
and interinvestigator variation. Efficacy assessments were performed Q4W
from week 16 to week 64 and at a withdrawal visit as soon as possible after
drug discontinuation. The pruritus VAS, pruritus verbal rating scale (VRS;
which measures pruritus intensity on a scale from 0 [no itch] to 4 [very severe
itch]), and sleep disturbance VAS (which ranges from 0 [no sleep loss] to
100 [inability to sleep at all]) were completed by patients every 7 days during
part B.Study end points
The primary efficacy end point, percentage improvement from baseline at
week 12 in pruritus VAS score, was assessed during part A. Secondary efficacy
end points assessed in part B (weeks 12-64) included improvement from
baseline values in the following: pruritus VAS score, Eczema Area and
Severity Index (EASI) score (range, 0-72, with higher scores indicating worse
disease severity), SCORing Atopic Dermatitis (SCORAD; range, 0-103, with
Screening Run-in
Nemolizumab 0.1 mg/kg Q4W, n = 13** to 8†
Nemolizumab 0.5 mg/kg Q4W, n = 12** to 7†
 Nemolizumab 2.0 mg/kg Q4W, n = 13** to 8†
UF ytefaS)B trap( tnemtaert mret-gnoL)A trap( doirep dellortnoc-obecalP ‡
Nemolizumab 0.1 mg/kg  Q4W, n = 41** to 31†
Nemolizumab 0.5 mg/kg Q4W, n = 38** to 28†
Nemolizumab 2.0 mg/kg Q4W, n = 39** to 30†
Nemolizumab 2.0 mg/kg Q8W*, n = 35** to 19†
Emollients
Mild (lowest) TCS/TCI, as needed
Rescue (potent/very potent TCS)Rescue (potent TCS)
(Placebo: Rerandomized to active groups)
Inclusion 
criteria
VAS ≥50 mm
EASI ≥10
sIGA ≥3
–4w –1w 0w 4w 8w 12w 64w
Patients who meet 
all criteria are 
randomized at 
Day –1 (1:1:1:1:1)
No
rescue
Nemolizumab 0.1 mg/kg  Q4W, n = 53
Nemolizumab 0.5 mg/kg Q4W, n = 54
Nemolizumab 2.0 mg/kg Q4W, n = 52
Nemolizumab 2.0 mg/kg Q8W*, n = 52
Placebo Q4W, n = 53
n = 264
FIG 1. Study design. *Patients in the nemolizumab 2.0 mg/kg Q8W group received placebo at week 4 during
part A; during part B, patients received placebo at week 12, nemolizumab at week 16, and then alternating
doses of placebo and nemolizumab. **Number of patients who randomized to part B. Number of patients
at week 64. Safety follow-up was performed 12 weeks after the last dose of study drug. FU, Follow-up;
TCI, topical calcineurin inhibitor; TCS, topical glucocorticosteroid; w, week.
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involvement, and sleep disturbance VAS score. Secondary end points also
included the proportion of patients with 25%, 50%, and 75% improvement
from baseline in pruritus VAS and EASI scores; the proportion of patients with
a 2-point or greater improvement from baseline in sIGA and pruritus VRS
scores; and the proportion of patients receiving rescue therapy. The proportion
of patients who achieved a pruritus VAS score of less than 30 mm (no or mild
itch)18 was explored in a post hoc analysis.
Exploratory efficacy outcomes in part B included the frequency, duration,
and amount of topical glucocorticosteroid used as a rescue therapy and
Dermatology Life Quality Index score (DLQI; measured on a scale of 0-30,
with higher scores representing greater impairment). A change in DLQI score
of 4 points or greater, which was considered a minimal clinically important
difference,19 was explored in a post hoc analysis. The long-term safety profile
was also evaluated.
Statistical analyses
Determination of sample size has been described previously.16 Secondary
and exploratory end points in part B were summarized by using descriptive
statistics, and no formal statistical comparisons were performed in part B.
No imputation was performed for missing data. Data measured during or after
rescue therapy were included in the analyses. The intent-to-treat population,
which included all randomized patients who had received at least 1 dose of
nemolizumab in part A or B and had at least 1 postdose efficacy assessment,
was used for efficacy analyses. All patients who had received at least 1 dose of
nemolizumab in part A or B were included in the safety analyses. Efficacy and
safety analyses were performed separately for patients who received
nemolizumab throughout the 64-week study period (patients randomized to
nemolizumab in part A and B) and patients who switched from placebo to
nemolizumab at week 12 (patients randomized to placebo in part A and
rerandomized to nemolizumab in part B).RESULTS
In total, 264 patients were randomized to part A; of these, 216
completed part A, and 191 participated in part B, including 38
rerandomized from the placebo group (see Fig E1 in this article’sOnline Repository at www.jacionline.org). Of the 191 patients
who participated in part B, 131 (69%) completed part B. The
most common reasons for discontinuation from part B were
patient withdrawal from the study (33/191 [17%]), followed by
lack of efficacy (10/191 [5%]) and AEs (8/191 [4%]). The
intent-to-treat population included 248 patients (211 patients
randomized to nemolizumab in part A and 37 patients
rerandomized to nemolizumab who received placebo in part
A [1 rerandomized patient had no evaluable postdose efficacy
data]). The safety population included 249 patients (211
randomized to nemolizumab in part A and 38 rerandomized to
nemolizumab who received placebo in part A). Overall, 84%
(222/264) of patients who entered the study in part A or B
completed a safety follow-up 12 weeks after the last dose of study
medication.Baseline demographics and disease characteristics
Demographics and baseline characteristics for patients
participating in part A have been reported.16 Patients had intense
itch at baseline according to the pruritus VAS scale score and
moderate-to-severe disease according to the sIGA, BSA affected
by AD, and EASI scores.16 Mean baseline total serum IgE levels
are reported in Table E1 in this article’s Online Repository at
www.jacionline.org. The most common current accompanying
allergy was allergic rhinitis (n 5 91), and the most frequent
history of allergy was asthma (n 5 34). Demographics, baseline
characteristics, and baseline severity of AD among patients
receiving placebo in part A who were rerandomized to
nemolizumab Q4W in part B were similar between groups.Efficacy
The improvement from baseline in pruritus VAS score
observed in part A was maintained or increased from week 12
Part A Part B
Patient number at each time point
0.1 mg/kg Q4W 53 51 47 45 41 37 37 36 33 32 32 32 32 31 30 29 29
0.5 mg/kg Q4W 54 53 46 45 38 35 34 32 28 30 30 29 29 27 27 26 26
2.0 mg/kg Q4W 51 50 48 47 37 35 32 34 33 31 31 31 29 31 30 30 28
2.0 mg/kg Q8W 50 47 45 39 32 29 28 25 25 23 23 21 19 19 19 19 18
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FIG 2. Pruritus VAS (ITT population who received nemolizumab in part A, including data after rescue
therapy). A, Percentage change from baseline in pruritus VAS score. Data are presented as means (SEs).
B, Proportion of patients with a pruritus VAS score of less than 30mm (post hoc analysis). ITT, Intent-to-treat.
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throughout the 64-week study period (Fig 2, A). The
greatest improvement throughout the study was observed in the
0.5-mg/kg nemolizumab group (Table I). The proportion of
patients who achieved a pruritus VAS score of less than 30 mm
was maintained until week 64 (Fig 2, B, and Table I). The
mean 6 SD percentage change from baseline in EASI score,
SCORAD score, BSA affected, and sleep disturbance VAS score
and the proportion of patients with a 2-point or greater
improvement in sIGA or pruritus VRS scores were also
maintained or increased from week 12 to week 64 in patients
who had received nemolizumab in part A (Fig 3, A-C, and
Table I). Approximately two thirds (68%, 68%, and 66%) of
patients in the 0.1-, 0.5-, and 2.0-mg/kg Q4W nemolizumab
groups, respectively, and almost three quarters (74%) of patients
in the 2.0-mg/kgQ8Wgroupwho remained on therapy at week 64
had a 75% improvement in EASI score (Table II).
In patients who received placebo in part A and switched to
nemolizumab at week 12, a response to treatment in pruritus VAS
score was seen by week 16 (ie, 4 weeks after switch to active
treatment) and maintained through week 64 (1 year after the
switch to active treatment, see Table E2 in this article’s Online
Repository at www.jacionline.org). Generally, mean 6 SD
percentage change from week 12 baseline to week 16 in
SCORAD score, EASI score, BSA affected, and sleep disturbanceVAS score indicated improvement that was maintained or
increased from week 16 to week 64 (see Table E2). However,
these data were affected by outlier values in the small number
of patients included in each group, with a high degree of
variability seen at each visit (see Table E2).Topical glucocorticosteroid use
In patients randomized to receive nemolizumab throughout
the 64-week study period, median duration of topical
glucocorticosteroid use was lower with increasing nemolizumab
dose at or greater than 0.5 mg/kg, from 27.0 weeks (range,
1-62 weeks) in the 0.1-mg/kg Q4W group to 8.0 weeks (range,
1-57 weeks) and 7.5 weeks (range, 1-59 weeks) in the 0.5- and
2.0-mg/kg Q4W groups, respectively, and 3.0 weeks (range,
1-48 weeks) in the 2.0-mg/kg Q8W group (see Table E3 in this
article’s Online Repository at www.jacionline.org). Median
cumulative dose of topical glucocorticosteroid therapy was also
lower with increasing nemolizumab dose at or greater than
0.5 mg/kg, from 137.4 g (range, 2-2,245 g) in the 0.1-mg/kg
Q4W group to 60.7 g (range, 2-822 g), 55.8 g (range,
1-1,174 g), and 44.7 g (range, 10-250 g) in the 0.5- and
2.0-mg/kg Q4W and 2.0-mg/kg Q8W groups, respectively (see
Table E3). However, there was a high degree of variation between
patients for duration and dose of topical glucocorticosteroid
TABLE I. Percentage change from baseline in secondary and exploratory end points at week 12 and week 64 (ITT population who
received nemolizumab in part A, includes data after rescue therapy)
End point
Nemolizumab
0.1 mg/kg Q4W (n 5 53) 0.5 mg/kg Q4W (n 5 54) 2.0 mg/kg Q4W (n 5 52) 2.0 mg/kg Q8W (n 5 52)
Percentage change in pruritus VAS score, mean 6 SD
Week 12 (n 5 45)
248.6 6 28.3
(n 5 45)
266.3 6 33.7
(n 5 46)
266.3 6 29.0
(n 5 39)
264.1 6 31.6
Week 64 (n 5 29)
273.0 6 28.4
(n 5 26)
289.6 6 11.2
(n 5 28)
274.7 6 28.4
(n 5 18)
279.1 6 24.2
Patients with pruritus VAS score <30 mm,* no. (%)
Week 12 (n 5 45)
14 (31)
(n 5 45)
30 (67)
(n 5 47)
29 (62)
(n 5 39)
23 (59)
Week 64 (n 5 29)
22 (76)
(n 5 26)
25 (96)
(n 5 28)
21 (75)
(n 5 18)
14 (78)
Percentage change in EASI score, mean 6 SD
Week 12 (n 5 45)
235.1 6 47.9
(n 5 46)
247.8 6 45.4
(n 5 46)
246.8 6 35.2
(n 5 37)
242.1 6 40.8
Week 64 (n 5 31)
268.5 6 41.6
(n 5 28)
275.8 6 25.4
(n 5 29)
278.9 6 24.3
(n 5 19)
269.3 6 44.0
Percentage change in SCORAD score, mean 6 SD
Week 12 (n 5 39)
236.4 6 22.2
(n 5 40)
242.2 6 30.7
(n 5 41)
242.6 6 27.1
(n 5 32)
241.9 6 20.8
Week 64 (n 5 28)
256.6 6 28.3
(n 5 23)
264.0 6 27.7
(n 5 26)
266.6 6 19.9
(n 5 18)
263.1 6 28.0
Patients with >_2-point improvement in sIGA score, no. (%)
Week 12 (n 5 45)
12 (27)
(n 5 46)
16 (35)
(n 5 46)
11 (24)
(n 5 37)
7 (19)
Week 64 (n 5 31)
18 (58)
(n 5 28)
18 (64)
(n 5 29)
19 (66)
(n 5 19)
9 (47)
Patients with sIGA score of 0 or 1, no. (%)
Week 12 (n 5 45)
3 (7)
(n 5 46)
9 (20)
(n 5 46)
8 (17)
(n 5 37)
3 (8)
Week 64 (n 5 31)
11 (35)
(n 5 28)
9 (32)
(n 5 29)
11 (38)
(n 5 19)
6 (32)
Percentage change in BSA affected by AD, mean 6 SD
Week 12 (n 5 45)
224.5 6 49.8
(n 5 46)
225.3 6 63.4
(n 5 46)
225.9 6 44.4
(n 5 37)
218.6 6 52.3
Week 64 (n 5 31)
262.5 6 40.9
(n 5 28)
266.0 6 36.4
(n 5 29)
263.4 6 40.4
(n 5 19)
260.5 6 56.0
Patients with >_2-point improvement in pruritus VRS score, no. (%)
Week 12 (n 5 45)
10 (22)
(n 5 44)
24 (55)
(n 5 46)
17 (37)
(n 5 39)
21 (54)
Week 64 (n 5 29)
17 (59)
(n 5 26)
20 (77)
(n 5 28)
17 (61)
(n 5 18)
13 (72)
Percentage change in sleep disturbance VAS score, mean 6 SD
Week 12 (n 5 45)
256.9 6 34.4
(n 5 44)
267.8 6 42.5
(n 5 46)
262.0 6 52.2
(n 5 39)
266.9 6 34.4
Week 64 (n 5 29)
281.5 6 31.9
(n 5 26)
292.2 6 11.9
(n 5 28)
272.5 6 38.1
(n 5 18)
279.5 6 32.2
Patients with >_4-point decrease in DLQI score,* no. (%)
Week 12 (n 5 43)
31 (72)
(n 5 44)
27 (61)
(n 5 44)
34 (77)
(n 5 37)
25 (68)
Week 64 (n 5 30)
28 (93)
(n 5 27)
22 (81)
(n 5 28)
25 (89)
(n 5 18)
15 (83)
ITT, Intent-to-treat.
*Post hoc analysis.
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number of patients receiving glucocorticosteroid therapy
was limited (18/30, 17/24, and 20/27 in the 0.1-, 0.5-, and
2.0-mg/kg Q4W groups, respectively, and 11/24 in the
2.0-mg/kg Q8W group). The proportion of patients receiving‘‘very potent’’ topical glucocorticosteroids was similar among
groups, whereas the proportion of patients receiving ‘‘potent’’
agents was greatest in the lowest nemolizumab Q4W group
(63% [19/30] in the 0.1-mg/kg group, 42% [10/24] in the 0.5-
mg/kg group, and 56% [15/27] in the 2.0-mg/kg group). Duration
Patient number at each time point
0.1 mg/kg Q4W 53 51 48 45 38 38 38 35 34 34 32 32 31 31 31 31
0.5 mg/kg Q4W 54 53 45 46 38 35 32 31 30 30 30 30 29 27 28 28 28
2.0 mg/kg Q4W 52 50 47 46 38 36 37 34 34 33 32 32 32 32 32 32 29
2.0 mg/kg Q8W 52 46 42 37 34 31 29 27 25 24 22 20 20 19 19 19 19
Weeks
B traPA traP
Patient number at each time point
0.1 mg/kg Q4W 53 51 48 45 40 38 38 38 35 34 34 32 32 31 31 31 31
0.5 mg/kg Q4W 54 53 45 46 38 35 32 31 30 30 30 30 29 27 28 28 28
2.0 mg/kg Q4W 52 50 47 46 38 36 37 34 34 33 32 32 32 32 32 32 29
2.0 mg/kg Q8W 52 46 42 37 34 31 29 27 25 24 22 20 20 19 19 19 19
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FIG 3. Change from baseline in key secondary and exploratory end points (ITT population who received
nemolizumab in part A, includes data after rescue therapy). A, Percentage change in EASI score
(mean 6 SE). B, Proportion of patients with an sIGA score of 0 or 1 (percentage). C, Percentage change
from baseline in sleep disturbance VAS (mean 6 SE). D, Proportion of patients with a 4-point or greater
decrease in DLQI (percentage; post hoc analysis). ITT, Intent-to-treat.
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TABLE II. Patients with a 25%, 50%, and 75% improvement from baseline in pruritus VAS and EASI scores at week 12 and week 64
(ITT population who received nemolizumab in part A, includes data after rescue therapy)
End point
Nemolizumab
0.1 mg/kg Q4W (n 5 53) 0.5 mg/kg Q4W (n 5 54) 2.0 mg/kg Q4W (n 5 52) 2.0 mg/kg Q8W (n 5 52)
Week 12 Week 64 Week 12 Week 64 Week 12 Week 64 Week 12 Week 64
Pruritus VAS (n 5 45) (n 5 29) (n 5 45) (n 5 26) (n 5 46) (n 5 28) (n 5 39) (n 5 18)
25% 35 (78) 26 (90) 38 (84) 26 (100) 42 (91) 26 (93) 33 (85) 17 (94)
50% 22 (49) 23 (79) 32 (71) 26 (100) 31 (67) 22 (79) 29 (74) 16 (89)
75% 8 (18) 19 (66) 24 (53) 24 (92) 21 (46) 19 (68) 18 (46) 14 (78)
EASI (n 5 45) (n 5 31) (n 5 46) (n 5 28) (n 5 46) (n 5 29) (n 5 37) (n 5 19)
25% 27 (60) 27 (87) 32 (70) 28 (100) 34 (74) 27 (93) 27 (73) 17 (89)
50% 21 (47) 23 (74) 25 (54) 20 (71) 22 (48) 26 (90) 16 (43) 15 (79)
75% 13 (29) 21 (68) 18 (39) 19 (68) 11 (24) 19 (66) 8 (22) 14 (74)
Data are shown as numbers (percentages).
ITT, Intent-to-treat.
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evaluable patients tended to be lower with increasing dose for
patients receiving ‘‘potent,’’ ‘‘moderately potent,’’ and ‘‘weak’’
agents (see Table E3); available data were limited for ‘‘very
potent’’ agents.QoL
DLQI total score decreased progressively throughout the study
in patients randomized to nemolizumab Q4W and Q8W
throughout the 64-week period, with a greater proportion of
patients demonstrating a 4-point or greater decrease in total score
at week 64 versus week 12 (Fig 3,D, and Table I). A similar trend
was observed in patients who had received placebo in part
A (see Table E2).Safety
Overall, no new safety concerns were identified after long-term
use of nemolizumab. In patients randomized to receive
nemolizumab throughout the study period (64 weeks), a similar
proportion had at least 1 AE (83% to 89% of patients) or at least 1
treatment-related AE (37% to 48%) over the course of the study
(Table III). The most common AEs in these patients (>_5% of
patients randomized to nemolizumab throughout the study
period) were nasopharyngitis (27%), exacerbation of AD
(25%), increased blood creatine phosphokinase (11%), upper
respiratory tract infection (9%), headache (8%), peripheral edema
(6%), and impetigo (6%). The most common treatment-related
AEs (>_2% patients randomized to nemolizumab throughout the
study period) were exacerbation of AD (8%), upper respiratory
tract infection (4%), nasopharyngitis (4%), peripheral edema
(3%), increased blood creatine phosphokinase level (3%), and
injection-site reaction (2%). All treatment-related AEs, except
nasopharyngitis and injection-site reactions, occurred at a slightly
higher incidence in the 2.0-mg/kg Q4W group than in the other
study groups. The proportion of patients randomized to receive
nemolizumab throughout the 64-week study period who
experienced new-onset AEs decreased over time, with the
majority of AEs reported in the first 12 weeks of the study (see
Table E4 in this article’s Online Repository at www.jacionline.
org). The majority of AEs during the study were mild or
moderate in intensity. SAEs occurred in 9 (17%) patients
receiving 2.0 mg/kg nemolizumab Q8W versus 3 to 4 (6% to
8%) patients across the Q4W treatment groups (Table III). SixSAEs reported in 5 patients were considered related to study
therapy. Five patients (1 in the 0.5-mg/kg Q4W group, 2 in the
2.0-mg/kg Q4W group, and 2 in the 2.0-mg/kg Q8W group)
had 1 SAE of exacerbation of AD, which was considered
treatment related in 1 patient. The proportion of patients
experiencing new-onset SAEs was distributed evenly over the
study duration (see Table E4). After adjustment for drug
exposure, rates of AEs and SAEs in patients randomized to
nemolizumab for the 64-week study period were higher in the
2.0-mg/kg Q8W group than the 0.1-, 0.5-, and 2.0-mg/kg Q4W
groups (Table IV); however, no increase in specific AEs was
observed. Discontinuation of study therapy because of AEs in
patients randomized to receive nemolizumab throughout the
64-week study period occurred in 7 (13%), 3 (6%), 5 (10%),
and 6 (12%) patients in the nemolizumab 0.1-, 0.5-, and
2.0-mg/kg Q4W and 2.0-mg/kg Q8W groups, respectively (see
Table E5 in this article’s Online Repository at www.jacionline.
org). Ten patients discontinued the study prematurely because
of exacerbation of AD, all in part A.
In patients rerandomized from placebo to nemolizumab in part
B, AEs were reported in 67% to 92% of patients across treatment
groups (see Table E6 in this article’s Online Repository at
www.jacionline.org). The most frequent AEs were similar to
those seen during the study as a whole (see Table E6). One
SAE was reported in 1 patient who had received placebo during
part A. Two patients who received placebo during part
A discontinued treatment because of AEs after randomization
to nemolizumab in part B.
The majority of injection-related reactions (IRRs) occurred
during part A of the study, with no trend of a dose-related effect
(12 patients had 13 events in part A and 4 patients had 5 events in
part B). Almost all IRRs were local reactions, predominantly mild
in severity, and were mostly considered treatment related. One
IRR resulted in discontinuation of study treatment (dermatitis
exfoliative).DISCUSSION
We describe a double-blind, randomized, long-term
extension study that evaluated the efficacy and tolerability of
nemolizumab, an anti–IL-31 receptor AmAb, for the treatment of
patients with AD inadequately controlled by using topical
therapy. The study demonstrated that improvements in pruritus,
dermatitis, and sleep measures versus placebo in the 12-week
placebo-controlled portion of the study (part A)16 were
TABLE III. AEs over the total 64-week study period in patients randomized to nemolizumab throughout the study period
(safety population, events reported during overall treatment period [baseline to 12 weeks after the last dose])
Event
Nemolizumab
0.1 mg/kg Q4W
(n 5 53)
0.5 mg/kg Q4W
(n 5 54)
2.0 mg/kg Q4W
(n 5 52)
2.0 mg/kg Q8W
(n 5 52)
Total no. of AEs 226 202 219 186
Patients with >_1 AE, no. (%) 47 (89) 46 (85) 45 (87) 43 (83)
Related to study treatment, no. (%) 20 (38) 20 (37) 25 (48) 19 (37)
Patients with >_1 SAE,* no. (%) 3 (6) 3 (6) 4 (8) 9 (17)
Related to study treatment, no. (%) 0 0 2 (4) 3 (6)
Patients with AEs leading to withdrawal from treatment, no. (%) 7 (13) 3 (6) 5 (10) 6 (12)
Related to study treatment, no. (%) 3 (6) 3 (6) 3 (6) 2 (4)
AEs in >_5% of patients, no. (%)
Nasopharyngitis 15 (28) 14 (26) 15 (29) 12 (23)
Exacerbation of AD 15 (28) 13 (24) 14 (27) 11 (21)
Increased blood creatine phosphokinase 5 (9) 3 (6) 9 (17) 6 (12)
Upper RTI 6 (11) 3 (6) 5 (10) 5 (10)
Headache 3 (6) 6 (11) 5 (10) 2 (4)
Peripheral edema 2 (4) 3 (6) 6 (12) 2 (4)
Impetigo 6 (11) 3 (6) 0 3 (6)
Influenza 5 (9) 1 (2) 2 (4) 0
Pharyngitis 1 (2) 3 (6) 3 (6) 1 (2)
Bronchitis 3 (6) 2 (4) 2 (4) 0
Cough 2 (4) 3 (6) 1 (2) 1 (2)
Arthralgia 1 (2) 2 (4) 3 (6) 2 (4)
Lymphadenopathy 3 (6) 1 (2) 1 (2) 2 (4)
Cystitis 1 (2) 3 (6) 1 (2) 1 (2)
Sinusitis 1 (2) 3 (6) 1 (2) 1 (2)
Urticaria 1 (2) 3 (6) 1 (2) 1 (2)
Folliculitis 1 (2) 0 1 (2) 3 (6)
Dizziness 3 (6) 0 0 2 (4)
Asthma 3 (6) 0 1 (2) 0
RTI, Respiratory tract infection.
*SAEs (number of events): exacerbation of AD (n 5 5), dermatitis exfoliative (n 5 1), rash (n 5 1), urticaria (n 5 1), infection (n 5 2), herpes simplex (n 5 1), herpes zoster
(n 5 1), pyelonephritis (n 5 1), pyoderma (n 5 1), skin infection (n 5 1), atrial fibrillation (n 5 1), coronary artery stenosis (n 5 1), grand mal convulsion (n 5 1), Parkinson
disease (n 5 1), lymphadenopathy (n 5 1), cataract (n 5 1), nonalcoholic steatohepatitis (n 5 1), joint dislocation (n 5 1), and upper limb fracture (n 5 1).
One patient withdrew from the study because of an AE after the last study drug injection and is not listed.
Peripheral edema was reported predominantly in the lower extremities and varied in duration (3-176 days). Severe peripheral edema was reported for 1 patient in the 0.1-mg/kg
Q4W group (edema of bilateral lower extremities) and 2 patients in the 2.0-mg/kg Q4W group (edema of legs and edema of bilateral upper extremities). Treatment was required for
6 patients overall across all treatment groups. No patients withdrew from the study owing to peripheral edema. No abnormalities related to the presentation of peripheral edema (eg,
renal or cardiac function) were reported.
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for up to 64 weeks (extension phase: part B). In keeping with
results from part A, although the study was not designed to
compare formally the different dose groups, there was no
evidence that 2.0 mg/kg nemolizumab administered Q4W or
Q8W was more effective than the 0.5-mg/kg dose. In part B
patients were allowed to use mild topical glucocorticosteroids,
with potent or very potent topical glucocorticosteroids permitted
as rescue therapy. Over the course of the study, the duration and
cumulative dose of concomitant topical glucocorticosteroid
therapy was lower in patients receiving higher (>_0.5 mg/kg) doses
of nemolizumab; however, limited patient numbers preclude any
conclusions. These findings propose that the absence of a
dose-dependent response, which would have resulted in increased
efficacy with higher doses of nemolizumab, might have been
affected by the greater use of topical glucocorticosteroid therapy
in patients in the 0.1-mg/kg group. Therefore concomitant use of
topical glucocorticosteroids might strengthen the antidermatitis
effect of nemolizumab and will be assessed in ongoing trials.20,21
AD and the accompanying pruritus impairs QoL in patients
with the disease.5,6,22 The reduction in DLQI scores observedduring part A of the study16 was maintained throughout the
long-term extension, suggesting prolonged alleviation of the
effect of symptoms on daily life. Although improvements in
efficacy end points were observed from week 16 in patients
who switched from placebo to nemolizumab at week 12, the small
number of patients in each dose group and the high attrition rate
and high degree of variability at each visit preclude drawing
conclusions. However, these findings are consistent with the early
improvement in pruritus observed within week 1 of nemolizumab
treatment in part A of the study.16
Overall, nemolizumab was well tolerated over 64 weeks. The
safety profile was comparable with that seen in part A, with no
new AEs observed in the extension study. The incidence of IRRs
was lower in part B, suggesting that tolerability to nemolizumab
injections improved over time.
AD is a T cell–mediated disease: TH2 cells are the predominant
source of the proinflammatory cytokine IL-31 in patients with AD
and trigger cytokine-induced itching through binding of IL-31 to
IL-31 receptor A on sensory neurons in the skin.10,12,13 In addition
to a role in pruritus, IL-31 might be involved in the recruitment of
inflammatory cells to affected skin areas, perpetuating the
TABLE IV. Exposure-adjusted AEs (safety population, events reported during exposure period [baseline to 4 weeks after last
dose])
Nemolizumab*
Placeboy
(n 5 53)
0.1 mg/kg Q4W
(n 5 53)
0.5 mg/kg Q4W
(n 5 54)
2.0 mg/kg Q4W
(n 5 52)
2.0 mg/kg Q8W
(n 5 52)
Total exposure period (patient-years) 11.4 45.6 42.4 45.1 35.0
AEs
Patients with >_1 AE, no. 36 47 45 45 42
Total no. of AEs, no. 105 208 193 211 172
Event/100 patient-years 924.1 455.9 455.1 468.3 491.3
Nasopharyngitis 70 70 68 49 60
Exacerbation of AD 70 42 35 36 34
Increased blood creatine phosphokinase 26 11 14 31 11
Upper RTI 62 18 19 20 14
Headache — 13 21 11 9
Peripheral edema — 7 7 18 9
Impetigo — 13 7 — 9
SAEs
Patients with >_1 SAE, no. 1 2 2 4 8
Total no. of SAEs 1 2 2 6 10
Event/100 patient-years 8.8 4.4 4.7 13.3 28.6
Event rates of AEs are presented as the number of events per 100 patient-years based on the ratio of observed number of events to total number of patient-years of exposure.
RTI, Respiratory tract infection.
*Patients who received nemolizumab during part A and part B.
Patients who received placebo during part A.
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The role of the IL-31 signaling pathway in immune regulation
remains to be fully elucidated and might be tissue specific.23-26
IL-31 also dysregulates the physical and functional properties
of the skin barrier, whereas low levels stimulate expression of
antimicrobial peptides.14 Therefore blocking IL-31–mediated
signaling can attenuate multiple pathogenic mechanisms in
patients with AD, although complete inhibition might be
undesirable.14
Treatment options are limited for patients with moderate-to-
severe AD that is inadequately controlled by topical treatments.
The systemic immunosuppressive therapy cyclosporine is used
for such patients but is associated with notable side effects,9,27
mostly on prolonged use. Therefore new agents with novel
mechanisms of action are required. The anti–IL-4 receptor a
mAb dupilumab demonstrated improvements in disease severity
and pruritus in patients with inadequately controlled AD28,29
and was recently approved in the United States and Europe.30,31
Although cross-trial comparisons should be considered with
caution because of different patient populations and study
designs, both dupilumab and nemolizumab might be new
treatment options for this difficult-to-treat patient population.
Nemolizumab therapy is under investigation in pediatric AD in
phase I and phase III studies21,32 supported by findings that IL-
31 mRNA expression is increased in skin biopsy specimens
from children with AD compared with adults with AD, including
in nonlesional skin.33
The limitations of the current study should be considered when
reviewing the findings. The study had a relatively small sample size
and a high attrition rate, with discontinuations predominantly caused
by patient withdrawal from the study. Therewas also no placebo arm
in part B of the study, which might have introduced bias because of
administration of only the active drug, and the studymight have been
affected by intersite and interinvestigator variability.
In summary, nemolizumab was efficacious and overall well
tolerated when administered for up to 64 weeks in patientswith moderate-to-severe AD that is inadequately controlled by
previous topical therapy. Treatment with nemolizumab resulted in
clinically meaningful reductions in pruritus and dermatitis. No
new safety concerns were identified with long-term nemolizumab
use. Our findings support previous observations for use of
nemolizumab in patients with moderate-to-severe AD15,16 and
encourage additional clinical trials to further evaluate the use of
nemolizumab in this setting.
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Clinical implications: Long-term phase II study data (up to
64 weeks) suggest that nemolizumab might be a new treatment
option in adults with moderate-to-severe AD that is controlled
inadequately by topical therapy.REFERENCES
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FIG E1. Patient disposition. Completion of safety follow-up for patients who received nemolizumab in part
A is the sum of patients who completed part A and a safety follow-up visit but who did not transition to part
B plus patients who completed part B and a safety follow-up visit.
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TABLE E1. Baseline total serum IgE levels (ITT population)
Placebo
(n 5 53)*
Nemolizumab
0.1 mg/kg Q4W
(n 5 53)
0.5 mg/kg Q4W
(n 5 54)
2.0 mg/kg Q4W
(n 5 52)
2.0 mg/kg Q8W
(n 5 52)
Total serum IgE levels (kU/L)
(n 5 53) (n 5 53) (n 5 54) (n 5 51) (n 5 52)
Mean 6,338 10,599 5,496 6,247 8,997
SD 11,389 15,919 9,074 17,182 20,433
ITT, Intent-to-treat.
*Patients who received placebo during part A.
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TABLE E2. Percentage change from baseline (week 12) in secondary and exploratory end points at week 16 (4 weeks after first
nemolizumab dose in part B) and week 64 (ITT population who received placebo in part A, includes data after rescue therapy)
End point
Patients rerandomized from placebo to nemolizumab in Part B
0.1 mg/kg Q4W (n 5 12) 0.5 mg/kg Q4W (n 5 12) 2.0 mg/kg Q4W (n 5 13)
Percentage change in pruritus VAS score, mean 6 SD
Week 16 (n 5 12)
233.3 6 35.4
(n 5 12)
239.3 6 33.1
(n 5 13)
255.5 6 30.3
Week 64 (n 5 8)
244.7 6 32.0
(n 5 5)
241.3 6 64.2
(n 5 6)
247.5 6 72.7
Percentage change in EASI score, mean 6 SD
Week 16 (n 5 12)
25.9 6 45.2
(n 5 12)
227.8 6 33.6
(n 5 11)
30.4 6 156.5
Week 64 (n 5 8)
262.7 6 19.4
(n 5 7)
6.3 6 171.2
(n 5 7)
252.9 6 65.2
Percentage change in SCORAD score, mean 6 SD
Week 16 (n 5 10)
212.3 6 19.2
(n 5 11)
222.5 6 25.5
(n 5 11)
221.6 6 34.4
Week 64 (n 5 6)
240.6 6 17.9
(n 5 6)
29.3 6 86.5
(n 5 7)
246.2 6 60.9
Percentage change in BSA affected by AD, mean 6 SD
Week 16 (n 5 12)
30.1 6 134.9
(n 5 12)
26.2 6 28.1
(n 5 11)
21.4 6 100.2
Week 64 (n 5 8)
233.0 6 29.6
(n 5 7)
250.4 6 59.4
(n 5 7)
264.6 6 42.0
Percentage change in sleep disturbance VAS, mean 6 SD
Week 16 (n 5 12)
220.5 6 41.0
(n 5 12)
246.6 6 40.1
(n 5 13)
252.5 6 33.9
Week 64 (n 5 8)
247.2 6 34.8
(n 5 5)
9.4 6 162.0
(n 5 6)
272.5 6 30.4
Proportion of patients with >_4-point decrease in DLQI score,* no. (%)
Week 16 (n 5 12)
6 (50)
(n 5 12)
8 (67)
(n 5 12)
10 (83)
Week 64 (n 5 8)
6 (75)
(n 5 7)
8 (86)
(n 5 8)
8 (100)
ITT, Intent-to-treat.
*Post hoc analysis.
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TABLE E3. Duration of use and cumulative dose of topical glucocorticosteroids throughout the study period from baseline* to end
of treatment overall and by potency* (ITT population who received nemolizumab in part A)
Topical glucocorticosteroid usey
Nemolizumab
0.1 mg/kg
Q4W (n 5 53)
0.5 mg/kg
Q4W (n 5 54)
2.0 mg/kg
Q4W (n 5 52)
2.0 mg/kg
Q8W (n 5 52)
Overall (n 5 18) (n 5 17) (n 5 20) (n 5 11)
Duration of use (wk) 27.0 (1-62) 8.0 (1-57) 7.5 (1-59) 3.0 (1-48)
Cumulative amount used (g) 137.4 (2-2,245) 60.7 (2-822) 55.8 (1-1,174) 44.7 (10-250)
By potency
Very potent (n 5 1) (n 5 2) (n 5 0) (n 5 0)
Duration of use (wk) 1.0 40.0 (40-40) — —
Cumulative amount used (g) 1.9 129.1 (60-198) — —
Potent (n 5 13) (n 5 9) (n 5 12) (n 5 7)
Duration of use (wk) 14.0 (2-62) 4.0 (1-23) 5.5 (1-24) 3.0 (1-4)
Cumulative amount used (g) 72.0 (24-1,015) 19.2 (2-38) 21.2 (1-166) 32.8 (12-200)
Moderately potent (n 5 9) (n 5 8) (n 5 6) (n 5 4)
Duration of use (wk) 24.0 (3-62) 6.0 (2-51) 6.0 (1-59) 2.5 (2-4)
Cumulative amount used (g) 70.2 (3-214) 63.2 (6-586) 50.7 (2-1,174) 7.1 (2-39)
Weak (n 5 3) (n 5 5) (n 5 4) (n 5 4)
Duration of use (wk) 28.0 (21-52) 23.0 (1-36) 9.0 (4-13) 3.5 (1-9)
Cumulative amount used (g) 581.0 (96-620) 41.5 (6-635) 108.1 (18-271) 11.6 (2-80)
Unknown (n 5 4) (n 5 5) (n 5 2) (n 5 3)
Duration of use (wk) 22.5 (3-52) 8.0 (3-52) 50.5 (49-52) 29.0 (4-48)
Cumulative amount used (g) 87.4 (33-2,218) 9.5 (2-320) 415.8 (89-743) 100.0 (45-105)
Data are shown as medians (ranges).
ITT, Intent-to-treat.
*Baseline values are unavailable (zero) because patients were not permitted to use potent or very potent topical glucocorticosteroids within 2 weeks before randomization or mild
or moderately potent topical glucocorticosteroids within 1 week before randomization. Use of topical glucocorticosteroids was not permitted during part A of the study, except as a
rescue therapy at or after week 4 (see Ruzicka T, et al. Anti-interleukin-31 receptor A antibody for atopic dermatitis. N Engl J Med 2017;376:826-35).
Potency of topical glucocorticosteroids, as defined by the National Institute for Health and Care Excellence (see Atopic eczema in children. Management of atopic eczema in
children from birth up to the age of 12 years. Clinical guideline. 2007. Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0009229/pdf/PubMedHealth_PMH0009229.
pdf. Accessed March 1, 2017).
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TABLE E4. New-onset AEs and SAEs by time period in patients randomized to receive nemolizumab throughout the study period
(safety population)
Period
Any period 0-12 wk >12-24 wk >24-36 wk >36-48 wk >48-64 wk Follow-up
AEs
Nemolizumab, 0.1 mg/kg Q4W
No. of patients 53 53 41 38 33 32 51
Patients with any AE, no. (%) 47 (89) 37 (70) 6 (15) 3 (8) 1 (3) — —
Nemolizumab, 0.5 mg/kg Q4W
No. of patients 54 54 38 34 30 30 49
Patients with any AE, no. (%) 46 (85) 37 (69) 5 (13) 1 (3) — 2 (7) 1 (2)
Nemolizumab, 2.0 mg/kg Q4W
No. of patients 52 52 39 36 33 32 49
Patients with any AE, no. (%) 45 (87) 39 (75) 2 (5) 1 (3) 2 (6) — —
Nemolizumab, 2.0 mg/kg Q8W
No. of patients 52 52 35 30 25 20 43
Patients with any AE, no. (%) 43 (83) 38 (73) 1 (3) 3 (10) — — 1 (2)
SAEs
Nemolizumab, 0.1 mg/kg Q4W
No. of patients 53 53 41 38 33 32 51
Patients with any SAE, no. (%) 3 (6) 1 (2) — — 1 (3) — 1 (2)
Nemolizumab, 0.5 mg/kg Q4W
No. of patients 54 54 38 34 30 30 49
Patients with any SAE, no. (%) 3 (6) — — — — 2 (7) 1 (2)
Nemolizumab, 2.0 mg/kg Q4W
No. of patients 52 52 39 36 33 32 49
Patients with any SAE, no. (%) 4 (8) 3 (6) 1 (3) — — — —
Nemolizumab, 2.0 mg/kg Q8W
No. of patients 52 52 35 30 25 20 43
Patients with any SAE, no. (%) 9 (17) 4 (8) 2 (6) 1 (3) 1 (4) 1 (5) 1 (2)
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TABLE E5. AEs leading to withdrawal from treatment in patients randomized to nemolizumab throughout the study period
(safety population, events reported during overall treatment period [baseline to 12 weeks following last dose])
Event
Nemolizumab
0.1 mg/kg Q4W (n 5 53) 0.5 mg/kg Q4W (n 5 54) 2.0 mg/kg Q4W (n 5 52) 2.0 mg/kg Q8W (n 5 52)
Patients with AEs leading to withdrawal
from treatment, no. (%)
7 (13) 3 (6) 5 (10) 6 (12)*
Total no. of events 7 5 8 7
Exacerbation of AD 2 3 3 2
Impetigo 1 0 0 1
Kaposi varicelliform eruption 1 0 0 1
Lymphadenopathy 1 0 1 0
Skin infection 0 1 1 0
Asthma 1 0 0 0
Atopic keratoconjunctivitis 0 0 1 0
Dermal cyst 1 0 0 0
Dermatitis exfoliative 0 0 0 1
Erysipelas 0 0 1 0
Grand mal convulsion 0 0 0 1
Palindromic rheumatism 0 0 1 0
Restlessness 0 1 0 0
Sinus tachycardia 0 0 0 1
*One patient withdrew from the study because of an AE after the last study drug injection and is not listed.
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TABLE E6. AEs in part B in patients randomized to receive placebo in part A (safety population)
Event
Patients rerandomized from placebo to nemolizumab in part B
0.1 mg/kg Q4W (n 5 13) 0.5 mg/kg Q4W (n 5 12) 2.0 mg/kg Q4W (n 5 13)
Total no. of AEs 37 27 57
Patients with >_1 AE, no. (%) 9 (69) 8 (67) 12 (92)
Related to study treatment, no. (%) 4 (31) 1 (8) 4 (31)
Patients with >_1 SAE, no. (%) 0 0 1 (8)*
Related to study treatment, no. (%) 0 0 1 (8)
Patients with AEs leading to withdrawal from treatment, no. (%) 1 (8) 0 1 (8)
Related to study treatment, no. (%) 1 (8) 0 1 (8)
AEs in >_2 patients, no. (%)
Nasopharyngitis 2 (15) 3 (25) 4 (31)
Exacerbation of AD 2 (15) 3 (25) 1 (8)
Increased blood creatine phosphokinase 2 (15) 1 (8) 2 (15)
Headache 2 (15) 1 (8) 1 (8)
Abdominal pain 1 (8) 0 1 (8)
Asthma 1 (8) 1 (8) 0
Back pain 0 1 (8) 1 (8)
Contact dermatitis 1 (8) 0 1 (8)
Contusion 0 0 2 (15)
Cough 1 (8) 0 1 (8)
Eyelid edema 1 (8) 0 1 (8)
Herpes zoster 0 0 2 (15)
Impetigo 1 (8) 1 (8) 0
Otitis externa 0 2 (17) 0
Peripheral edema 0 0 2 (15)
*SAE of diverticulitis.
Asthma.
Bronchial hyperreactivity.
J ALLERGY CLIN IMMUNOL
VOLUME 142, NUMBER 4
KABASHIMA ET AL 1130.e7
